NCT04499508

Brief Summary

In recent years, many developments have been made to the tools and techniques used to treat IAs via endovascular intervention. Specifically, to the detachable coils themselves. In March 2018, the US Food and Drug administration granted Balt USA 510(k) clearance for the Optima Coil System™. Earlier this year, the list of devices included within the system has expanded to include OptiMAX Complex Super Soft and Complex Soft coils. It consists of coils that come in Standard, Soft and Super Soft profiles and allows for instant detachment from the pusher. The APPLY study is a prospective, single-center investigator-initiated study meant to assess the use of the Balt Optima™ Coil System. The site is looking to enroll approximately 30 subjects over the course of two years. The Optima Coil System™ is commercially available in the United States as such this study is looking for real-world data.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 10, 2020

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 28, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 5, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 9, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 9, 2023

Completed
Last Updated

April 26, 2022

Status Verified

April 1, 2022

Enrollment Period

3 years

First QC Date

July 28, 2020

Last Update Submit

April 25, 2022

Conditions

Keywords

Brain aneurysmOptima Coil SystemEndovascular CoilingEmbolizationRuptured Intracranial AneurysmUnruptured Intracranial Aneurysm

Outcome Measures

Primary Outcomes (2)

  • Occlusion Rates

    Successful occlusion rates defined as Raymond-Roy Occlusion Class I and II.

    12 Months

  • Mortality

    All-cause mortality.

    12 Months

Secondary Outcomes (8)

  • Occlusion Scale Score

    Immediately post-procedure, 3-Months, and 12-Months

  • Modified Rankin Scale (mRS)

    Up to 1 year during various scheduled visits. Specifically, at discharge from hospital, at 3-month follow up and again at 12-months.

  • Packing Density

    Result is known immediately post-procedure.

  • Fluro Time

    Result is known immediately post-procedure.

  • Other Devices Used

    Result is known immediately post-procedure.

  • +3 more secondary outcomes

Study Arms (1)

Treatment with Optima Balt Coils

EXPERIMENTAL

The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.

Device: Optima Coil System

Interventions

Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with

Also known as: Embolization of Intracranial Aneurysm, Optima Balt Coil System, Neurovascular Embolization Device
Treatment with Optima Balt Coils

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients age ≥ 18
  • Patients undergoing the embolization of large or small intracranial aneurysms
  • Patient's physician has decided that the best treatment for the patient's neurovascular abnormalities is the Optima Coil System and the patient has agreed to the treatment
  • Of the total number of coils implanted Optima™ Coil System accounts for at least 80%
  • Fully executed IRB approved Informed Consent

You may not qualify if:

  • Patient participation in another study that may disrupt the results of this study
  • Anticipated life expectancy of less than 12-months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vascular Neurology of Southern California

Thousand Oaks, California, 91360, United States

RECRUITING

Related Publications (12)

  • Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, Sandercock P; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005 Sep 3-9;366(9488):809-17. doi: 10.1016/S0140-6736(05)67214-5.

    PMID: 16139655BACKGROUND
  • Yoo E, Kim DJ, Kim DI, Lee JW, Suh SH. Bailout stent deployment during coil embolization of intracranial aneurysms. AJNR Am J Neuroradiol. 2009 May;30(5):1028-34. doi: 10.3174/ajnr.A1482. Epub 2009 Feb 4.

    PMID: 19193745BACKGROUND
  • Frazer D, Ahuja A, Watkins L, Cipolotti L. Coiling versus clipping for the treatment of aneurysmal subarachnoid hemorrhage: a longitudinal investigation into cognitive outcome. Neurosurgery. 2007 Mar;60(3):434-41; discussion 441-2. doi: 10.1227/01.NEU.0000255335.72662.25.

    PMID: 17327787BACKGROUND
  • Jalbert JJ, Isaacs AJ, Kamel H, Sedrakyan A. Clipping and Coiling of Unruptured Intracranial Aneurysms Among Medicare Beneficiaries, 2000 to 2010. Stroke. 2015 Sep;46(9):2452-7. doi: 10.1161/STROKEAHA.115.009777. Epub 2015 Aug 6.

    PMID: 26251248BACKGROUND
  • Guglielmi G. History of endovascular endosaccular occlusion of brain aneurysms: 1965-1990. Interv Neuroradiol. 2007 Sep;13(3):217-24. doi: 10.1177/159101990701300301. Epub 2007 Sep 15.

    PMID: 20566113BACKGROUND
  • Katsaridis V, Papagiannaki C, Violaris C. Guglielmi detachable coils versus matrix coils: a comparison of the immediate posttreatment results of the embolization of 364 cerebral aneurysms in 307 patients: a single-center, single-surgeon experience. AJNR Am J Neuroradiol. 2006 Oct;27(9):1841-8.

    PMID: 17032854BACKGROUND
  • Tamatani S, Ito Y, Abe H, Koike T, Takeuchi S, Tanaka R. Evaluation of the stability of aneurysms after embolization using detachable coils: correlation between stability of aneurysms and embolized volume of aneurysms. AJNR Am J Neuroradiol. 2002 May;23(5):762-7.

    PMID: 12006273BACKGROUND
  • Ayling OG, Ibrahim GM, Drake B, Torner JC, Macdonald RL. Operative complications and differences in outcome after clipping and coiling of ruptured intracranial aneurysms. J Neurosurg. 2015 Sep;123(3):621-8. doi: 10.3171/2014.11.JNS141607. Epub 2015 Jun 5.

    PMID: 26047409BACKGROUND
  • Mascitelli JR, Moyle H, Oermann EK, Polykarpou MF, Patel AA, Doshi AH, Gologorsky Y, Bederson JB, Patel AB. An update to the Raymond-Roy Occlusion Classification of intracranial aneurysms treated with coil embolization. J Neurointerv Surg. 2015 Jul;7(7):496-502. doi: 10.1136/neurintsurg-2014-011258. Epub 2014 Jun 4.

    PMID: 24898735BACKGROUND
  • Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968 Jan;28(1):14-20. doi: 10.3171/jns.1968.28.1.0014. No abstract available.

    PMID: 5635959BACKGROUND
  • van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7. doi: 10.1161/01.str.19.5.604.

    PMID: 3363593BACKGROUND
  • Brilstra EH, Rinkel GJ, van der Graaf Y, van Rooij WJ, Algra A. Treatment of intracranial aneurysms by embolization with coils: a systematic review. Stroke. 1999 Feb;30(2):470-6. doi: 10.1161/01.str.30.2.470.

MeSH Terms

Conditions

AneurysmIntracranial AneurysmAneurysm, RupturedSubarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesIntracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesIntracranial HemorrhagesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Muhammad A Taqi, MD

    Vascular Neurology of Southern California

    PRINCIPAL INVESTIGATOR
  • Anastasia Vechera, BA

    Vascular Neurology of Southern California

    STUDY DIRECTOR

Central Study Contacts

Anastasia Vechera, BA

CONTACT

Muhammad A Taqi, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: This is a prospective, single-arm, single-center, post-market, real-world, investigator-initiated study.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2020

First Posted

August 5, 2020

Study Start

April 10, 2020

Primary Completion

April 9, 2023

Study Completion

April 9, 2023

Last Updated

April 26, 2022

Record last verified: 2022-04

Locations